I. Cestonaro

297P The genetic profile of primary and recurrent gliomas: A mono-institutional experience using next-generation sequencing

V. Zagonel, G. Lombardi, M. Maccari, 2022, Annals of Oncology.

P02.02.A Next-generation sequencing (NGS) for identifying actionable molecular alterations in newly diagnosed and recurrent IDHwt-glioblastoma (GBM) patients: a large mono institutional experience

M. Fassan, V. Zagonel, G. Lombardi, 2022, Neuro-Oncology.

Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis.

V. Zagonel, G. Lombardi, M. Caccese, 2023, European journal of cancer.

Repurposing Chlorpromazine as add-on in the adjuvant phase of first-line glioblastoma therapeutic protocol in patients carrying hypo-/un-methylated MGMT gene promoter: RACTAC, a Phase II multicenter single arm clinical trial

A. Silvani, P. Gaviani, D. Giannarelli, 2023, medRxiv.

Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial

P. Gaviani, M. Caccese, G. Cerretti, 2023, Frontiers in oncology.